Accretion Pha. — 360° view

Accretion Pha, a company in the Pharmaceuticals industry, reported revenue of ₹55 crore and net profit of ₹8.00 crore for the September 2026 quarter.

Accretion Pha. (NSE: ACCPL-ST) closed at ₹207.00 on 20 Nov 2026, up 149.7% over the past year. Its market capitalisation is ₹230 crore and it trades at 17.5 times earnings.

Share price
₹207.00 (20 Nov 2026)
Market cap
₹230 Cr (20 Nov 2026)
P/E
17.54 (20 Nov 2026)
Revenue
₹55 Cr (September 2026 quarter)
Net profit
₹8 Cr (September 2026 quarter)
ROCE
28.9% (FY26)
ROE
27.6% (FY26)
Book value
₹56.6 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹220.00 / ₹62.00 (20 Nov 2026)
1-year return
149.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ACCPL-ST

Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.